Modelling drug resistance and its implications in cell-cycle phase specific chemotherapy
figure10-eps-converted-to
Plots showing the spatial evolution of cancer cells within a two-population model when single dose of cell-cycle phase-specific chemotherapeutic drugs are given.

The development of drug resistance by cancer cells continues to be a key impediment in the successful delivery of these multi-drug therapies. Recent studies have indicated that intra-tumoural heterogeneity has a significant role in driving resistance to chemotherapy in many human malignancies. Multiple factors, including the internal cell-cycle dynamics and external microenvironement contribute to the intra-tumoral heterogeneity. Our recent studies has indicated the role on slow-cycling tumour sub-populations in developing resistance to conventional chemotherapeutic drug.

Relevant Publications:
  • G.G. Powathil, K.E. Gordon, L.A. Hill, M.A.J. Chaplain, Modelling the effects of cell-cycle heterogeneity on tumour response to chemotherapy: Biological insights from a hybrid multi-scale cellular automaton model, Journal of Theoretical Biology 2012,308:1, doi: 10.1016/j.jtbi.2012.05.015
  • G.G. Powathil, M.A.J. Chaplain, M. Swat, Investigating the development of chemotherapeutic drug resistance in cancer: A multiscale computational study, arXiv 2014, http://arxiv.org/abs/1407.0865